
  
    
      
        Background_NNP
        Pelvic_NNP floor_NN disorders_NNS (_( PFD_NNP )_) are_VBP highly_RB prevalent_JJ among_IN
        elderly_JJ women_NNS ._. Many_JJ surgical_JJ reports_NNS attempt_VBP to_TO determine_VB
        the_DT best_JJS surgical_JJ treatment_NN for_IN PFD_NNP ,_, yet_RB do_VBP not_RB address_VB the_DT
        pathophysiology_NN ._. The_DT etiology_NN of_IN PFD_NNP is_VBZ probably_RB
        multifactorial_NN ,_, including_VBG a_DT genetic_JJ predisposition_NN to_TO
        connective_JJ tissue_NN abnormalities_NNS ,_, vaginal_JJ childbirth_NN with_IN
        damage_NN to_TO the_DT innervation_NN of_IN the_DT pelvic_JJ floor_NN muscles_NNS ,_,
        estrogen_NN deficiency_NN ,_, and_CC aging_VBG effects_NNS [_NN 1_CD ]_NN ._. The_DT pelvic_JJ
        floor_NN ,_, situated_VBN at_IN the_DT bottom_NN of_IN the_DT abdominal_NN cavity_NN ,_,
        forms_VBZ a_DT supporting_VBG shelf_NN for_IN the_DT abdominal_NN and_CC pelvic_JJ
        viscera_NN ._. It_PRP has_VBZ three_CD layers_NNS :_: the_DT endopelvic_JJ fascia_NN ,_, the_DT
        levator_NN fasciae_NN and_CC muscles_NNS ,_, and_CC the_DT perineal_NN
        membrane_NN /_NN external_JJ anal_NN sphincter_NN ._.
        The_DT primary_JJ support_NN for_IN the_DT pelvic_JJ organs_NNS comes_VBZ from_IN the_DT
        pelvic_JJ floor_NN muscles_NNS [_NN 1_CD 2_CD ]_NN ._. This_DT suggests_VBZ that_IN an_DT
        alteration_NN to_TO the_DT levator_NN ani_NN supportive_JJ function_NN may_MD
        significantly_RB contribute_VB to_TO the_DT pathogenesis_NNS of_IN PFD_NNP [_NN 3_CD ]_NN ,_,
        which_WDT affect_VBP 5_CD %_NN of_IN younger_JJR and_CC nearly_RB 50_CD %_NN of_IN elderly_JJ women_NNS
        [_NN 2_CD ]_NN ._. In_IN women_NNS ,_, the_DT levator_NN muscles_NNS form_VBP a_DT horizontal_NN
        shelf_NN with_IN an_DT anterior_NN midline_NN cleft_NN (_( the_DT urogenital_NN
        hiatus_NN )_) through_IN which_WDT the_DT urethra_NN ,_, vagina_NN ,_, and_CC rectum_NN pass_NN ._.
        Anatomically_NNP ,_, the_DT levator_NN muscle_NN is_VBZ subdivided_JJ into_IN the_DT
        iliococcygeal_NN and_CC the_DT pubococcygeal_NN muscles_NNS [_NN 4_CD 5_CD ]_NN (_( Fig_NNP ._.
        1_LS )_) ._.
        The_DT levator_NN ani_NN muscles_NNS play_VBP an_DT important_JJ role_NN in_IN
        bladder_NN neck_NN fixation_NN provided_VBN by_IN the_DT suspensory_NN sling_VBG and_CC
        hiatal_NN ligament_NN [_NN 6_CD ]_NN ._. The_DT urethra_NN is_VBZ supported_VBN by_IN the_DT
        action_NN of_IN the_DT levator_NN ani_NN muscles_NNS through_IN their_PRP$ connection_NN
        to_TO the_DT endopelvic_JJ fascia_NN of_IN the_DT anterior_NN vaginal_JJ wall_NN [_NN 7_CD ]_NN
        ,_, and_CC the_DT muscles_NNS of_IN the_DT levator_NN ani_NN contract_NN during_IN a_DT
        cough_NN to_TO assist_VB continence_NN [_NN 8_CD ]_NN ._. The_DT fast_RB twitch_VB type_NN II_NNP
        fibers_NNS in_IN the_DT levator_NN ani_NN muscles_NNS play_VBP an_DT important_JJ role_NN in_IN
        continence_NN ,_, and_CC their_PRP$ loss_NN accompanies_VBZ the_DT development_NN of_IN
        urinary_JJ incontinence_NN [_NN 9_CD ]_NN ._. Clinically_NNP ,_, women_NNS with_IN
        recurrent_JJ urinary_JJ incontinence_NN after_IN Burch_NNP colposuspension_NN
        have_VBP a_DT more_RBR pronounced_JJ pelvic_JJ floor_NN weakness_NN than_IN women_NNS
        with_IN primary_JJ stress_NN urinary_JJ incontinence_NN [_NN 10_CD ]_NN ._. This_DT
        suggests_VBZ that_IN the_DT recurrent_JJ urinary_JJ incontinence_NN is_VBZ caused_VBN
        by_IN a_DT progression_NN of_IN pelvic_JJ floor_NN dysfunction_NN ._. Severe_NNP
        alteration_NN in_IN the_DT levator_NN ani_NN integrity_NN is_VBZ associated_VBN also_RB
        with_IN fecal_JJ incontinence_NN [_NN 11_CD 12_CD 13_CD ]_NN ._.
        Histologic_NNP and_CC histochemical_JJ analysis_NN of_IN pubococcygeal_NN
        muscle_NN obtained_VBN from_IN asymptomatic_JJ women_NNS and_CC from_IN women_NNS with_IN
        PFD_NNP has_VBZ shown_VBN that_IN both_DT age_NN and_CC parity_NN (_( vaginal_JJ delivery_NN )_)
        appeared_VBD to_TO be_VB related_VBN to_TO the_DT morphological_JJ features_NNS of_IN the_DT
        samples_NNS ._. In_IN the_DT symptomatic_JJ women_NNS there_RB was_VBD a_DT significant_JJ
        increase_NN in_IN the_DT number_NN of_IN muscle_NN fibers_NNS showing_VBG
        pathological_JJ damage_NN ._. The_DT range_NN of_IN diameters_NNS of_IN both_DT type_NN I_PRP
        and_CC II_NNP fibers_NNS was_VBD significantly_RB different_JJ between_IN
        symptomatic_JJ and_CC asymptomatic_JJ women_NNS ._. A_DT significant_JJ
        proportion_NN (_( 90_CD -_: 100_CD %_NN )_) of_IN muscle_NN fibers_NNS in_IN symptomatic_JJ women_NNS
        were_VBD type_NN I_PRP fibers_NNS ,_, showed_VBD centrally_RB located_VBN nuclei_NN ,_, and_CC
        exhibited_VBN significantly_RB greater_JJR diameter_NN than_IN type_NN I_PRP fibers_NNS
        in_IN asymptomatic_JJ women_NNS [_NN 3_CD ]_NN ._.
        However_RB ,_, the_DT cellular_JJ and_CC molecular_JJ aspects_NNS of_IN
        regression_NN of_IN type_NN II_NNP fibers_NNS are_VBP poorly_RB understood_VBN ._. Though_IN
        apoptosis_NNS in_IN adult_NN muscles_NNS has_VBZ been_VBN described_VBN ,_, and_CC may_MD
        result_VB from_IN changes_NNS within_IN bcl_NN 2_CD /_NN bax_NN system_NN ,_, alteration_NN in_IN
        pathways_NNS that_WDT regulate_VB differentiation_NN of_IN muscle_NN cells_NNS ,_,
        changes_NNS in_IN the_DT myonuclei_NN ,_, and_CC the_DT nature_NN of_IN pathways_NNS
        inducing_VBG senescence_NN of_IN skeletal_NN muscles_NNS are_VBP still_RB far_RB from_IN
        being_VBG clear_JJ [_NN 14_CD ]_NN ._.
        Among_IN cell_NN cycle_NN related_VBD proteins_NNS ,_, an_DT important_JJ role_NN in_IN
        the_DT regulation_NN of_IN skeletal_NN muscle_NN differentiation_NN belongs_VBZ
        to_TO p_NN 27_CD kip_NN 1_CD (_( p_NN 27_CD )_) protein_NN [_NN 15_CD ]_NN ,_, a_DT cyclin-dependent_JJ kinase_NN
        inhibitor_NN required_VBN for_IN cell_NN cycle_NN arrest_NN ._. Additionally_RB ,_,
        since_IN the_DT identification_NN and_CC cloning_VBG of_IN the_DT p_NN 27_CD gene_NN in_IN
        1994_CD [_NN 16_CD ]_NN ,_, the_DT p_NN 27_CD protein_NN has_VBZ been_VBN shown_VBN to_TO be_VB involved_VBN
        in_IN various_JJ other_JJ aspects_NNS of_IN cell_NN physiology_NN and_CC pathology_NN [_NN
        17_CD ]_NN ._. Our_PRP$ previous_JJ study_NN has_VBZ shown_VBN ,_, that_DT differentiation_NN
        of_IN cells_NNS in_IN tissue_NN culture_NN is_VBZ associated_VBN with_IN an_DT increase_NN
        in_IN p_NN 27_CD expression_NN [_NN 18_CD ]_NN ._. Although_IN a_DT regular_JJ p_NN 27_CD
        expression_NN protects_VBZ normal_JJ cells_NNS from_IN apoptosis_NNS ,_,
        overexpression_NN of_IN p_NN 27_CD induces_VBZ apoptosis_NNS of_IN cells_NNS ,_, through_IN
        elevation_NN of_IN proapoptotic_JJ proteins_NNS ,_, such_JJ as_IN Bax_NNP [_NN 19_CD 20_CD ]_NN ._.
        These_DT observations_NNS indicate_VBP that_IN changes_NNS in_IN p_NN 27_CD expression_NN
        can_MD determine_VB the_DT fate_NN of_IN muscle_NN cells_NNS ._.
        Aims_VBZ of_IN the_DT present_JJ study_NN were_VBD to_TO investigate_VB p_NN 27_CD
        expression_NN in_IN levator_NN ani_NN muscle_NN of_IN symptomatic_JJ women_NNS ,_,
        determine_VB changes_NNS with_IN age_NN ,_, and_CC compare_VB the_DT p_NN 27_CD expression_NN
        with_IN histochemical_JJ detection_NN of_IN fast-_NN and_CC slow_JJ twitch_VB
        muscle_NN fibers_NNS in_IN parallel_JJ sections_NNS ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Patients_NNS
          Biopsy_NNP samples_NNS 5_CD ×_NN 5_CD ×_NN 5_CD mm_NN were_VBD collected_VBN from_IN 22_CD
          symptomatic_JJ patients_NNS with_IN PFD_NNP (_( stress_NN urinary_JJ
          incontinence_NN ,_, pelvic_JJ organ_NN prolapse_NN ,_, fecal_JJ incontinence_NN ,_,
          and_CC overlaps_NNS ;_: age_NN range_NN 38_CD -_: 74_CD )_) without_IN hormone_NN
          replacement_NN therapy_NN ._. Besides_IN hormone_NN replacement_NN ,_, also_RB
          excluded_VBN from_IN the_DT study_NN were_VBD patients_NNS with_IN a_DT history_NN of_IN
          malignancy_NN ,_, endometriosis_NNS ,_, and_CC pelvic_JJ infections_NNS ._.
          Tissue_NNP sampling_VBG from_IN levator_NN ani_NN muscles_NNS and_CC fascia_NN ,_,
          illustrated_VBN in_IN Fig_NNP ._. 1_LS ,_, was_VBD based_VBN on_IN the_DT work_NN of_IN Bernstein_NNP
          [_NN 2_CD ]_NN (_( biopsy_NN size_NN and_CC site_NN )_) ,_, with_IN some_DT modifications_NNS
          approved_VBN by_IN the_DT Institutional_NNP Review_NNP Board_NNP ._. We_PRP used_VBD
          similar_JJ approaches_NNS to_TO obtain_VB the_DT biopsy_NN during_IN
          reconstructive_JJ surgery_NN (_( symptomatic_JJ patients_NNS )_) and_CC
          abdominal_NN hysterectomy_NN (_( asymptomatic_JJ controls_NNS )_) ._. The_DT
          biopsy_NN sample_NN was_VBD always_RB obtained_VBN from_IN the_DT right_JJ
          pubococcygeal_NN muscle_NN ._. The_DT biopsy_NN was_VBD lateral_NN (_( 20_CD -_: 25_CD mm_NN )_)
          to_TO the_DT urethrovesical_JJ junction_NN and_CC was_VBD performed_VBN midway_NN
          between_IN the_DT urethra_NN and_CC arcus_JJ tendinus_JJ (_( white_JJ line_NN )_) ._. It_PRP
          was_VBD lateral_NN enough_RB from_IN the_DT urethra_NN to_TO avoid_VB any_DT
          alteration_NN of_IN nerves_NNS to_TO the_DT urethra_NN and_CC bladder_NN ._.
          In_IN reconstructive_JJ surgery_NN ,_, on_IN entering_VBG the_DT space_NN of_IN
          Retzius_NNP ,_, the_DT fat_NN was_VBD pushed_VBN aside_RB to_TO expose_VB the_DT superior_JJ
          fascia_NN of_IN the_DT levator_NN ani_NN ._. After_IN incision_NN ,_, the_DT fascia_NN
          biopsy_NN specimen_NN (_( 5_CD ×_NN 5_CD mm_NN )_) was_VBD collected_VBN ._. Next_JJ ,_, the_DT Allis_NNP
          clamp_NN was_VBD used_VBN to_TO expose_VB a_DT small_JJ part_NN of_IN the_DT
          pubococcygeal_NN muscle_NN and_CC collect_VB a_DT 5_CD ×_NN 5_CD ×_NN 5_CD mm_NN muscle_NN
          biopsy_NN specimen_NN ._.
          For_IN comparison_NN ,_, biopsies_NNS were_VBD obtained_VBN from_IN nine_CD
          asymptomatic_JJ women_NNS (_( age_NN 31_CD -_: 49_CD )_) who_WP were_VBD having_VBG a_DT
          hysterectomy_NN for_IN benign_JJ conditions_NNS such_JJ as_IN abnormal_JJ
          uterine_NN bleeding_NN ,_, fibroids_NNS or_CC pelvic_JJ pain_NN ,_, and_CC no_DT hormone_NN
          replacement_NN therapy_NN ._. They_PRP did_VBD not_RB have_VB any_DT demonstrable_JJ
          pelvic_JJ relaxation_NN by_IN examination_NN or_CC history_NN of_IN stress_NN
          urinary_JJ incontinence_NN ._. We_PRP were_VBD unable_JJ ,_, during_IN a_DT two_CD year_NN
          period_NN ,_, collect_VB biopsies_NNS from_IN asymptomatic_JJ women_NNS of_IN age_NN
          50_CD or_CC older_JJR ._. The_DT apparent_JJ reason_NN for_IN this_DT is_VBZ that_IN ,_, except_IN
          for_IN urogynecological_JJ indications_NNS and_CC cancer_NN ,_, there_EX is_VBZ
          virtually_RB no_DT reason_NN for_IN abdominal_NN gynecologic_JJ surgery_NN in_IN
          postmenopausal_NN women_NNS ._. To_TO ensure_VB the_DT compatibility_NN of_IN
          biopsy_NN samples_NNS ,_, the_DT space_NN of_IN Retzius_NNP was_VBD opened_VBN in_IN all_DT
          patients_NNS ._.
          During_IN abdominal_NN hysterectomy_NN ,_, the_DT urinary_JJ bladder_NN was_VBD
          pushed_VBN down_RB to_TO reach_VB the_DT space_NN of_IN Retzius_NNP by_IN incision_NN
          right_NN behind_IN the_DT pubic_JJ bone_NN ._. The_DT fat_NN was_VBD pushed_VBN aside_RB
          with_IN the_DT assistance_NN of_IN a_DT hand_NN in_IN the_DT vagina_NN ,_, and_CC biopsy_NN
          was_VBD performed_VBN as_IN described_VBN ._. After_IN biopsy_NN ,_, a_DT single_JJ
          figure-of-eight_JJ stitch_NN suture_NN was_VBD placed_VBN in_IN all_DT patients_NNS ,_,
          which_WDT corrected_VBD any_DT potential_JJ loss_NN of_IN support_NN that_WDT might_MD
          be_VB caused_VBN by_IN the_DT biopsy_NN ._. This_DT was_VBD bloodless_JJ and_CC did_VBD not_RB
          create_VB any_DT lasting_JJ difficulties_NNS ._. None_NN of_IN the_DT control_NN
          patients_NNS developed_VBD urinary_JJ incontinence_NN or_CC evidence_NN of_IN
          loss_NN of_IN support_NN or_CC voiding_VBG difficulties_NNS ._.
          In_IN younger_JJR asymptomatic_JJ women_NNS ,_, we_PRP also_RB collected_VBD
          biopsy_NN samples_NNS of_IN ectocervix_NN and_CC endometrium_NN from_IN
          hysterectomy_NN specimens_NNS ._. These_DT samples_NNS were_VBD utilized_JJ to_TO
          determine_VB p_NN 27_CD expression_NN in_IN other_JJ tissues_NNS ,_, for_IN comparison_NN
          with_IN expression_NN in_IN the_DT skeletal_NN muscle_NN (_( Fig_NNP ._. 9_CD )_) ._. In_IN
          addition_NN ,_, we_PRP utilized_JJ our_PRP$ collection_NN of_IN frozen_VBN human_JJ
          corpora_NN lutea_NN (_( CL_NNP )_) ,_, from_IN which_WDT some_DT observations_NNS have_VBP
          been_VBN reported_VBN previously_RB [_NN 21_CD 22_CD 23_CD ]_NN ,_, in_IN order_NN to_TO
          determine_VB a_DT relationship_NN of_IN p_NN 27_CD expression_NN with_IN some_DT
          other_JJ cell_NN cycle_NN related_VBD proteins_NNS under_IN specific_JJ
          circumstances_NNS (_( Fig_NNP ._. 10_CD )_) ._. All_DT parts_NNS of_IN the_DT study_NN were_VBD
          approved_VBN by_IN the_DT Institutional_NNP Review_NNP Board_NNP at_IN our_PRP$
          University_NNP of_IN Tennessee_NNP Graduate_NNP School_NNP of_IN Medicine_NNP ._. All_DT
          women_NNS underwent_VBD the_DT informed_VBN consent_NN process_NN and_CC signed_VBD
          informed_VBN consent_NN forms_NNS before_IN participation_NN ._.
        
        
          Immunohistochemistry_NNP
          Biopsy_NNP samples_NNS were_VBD mounted_VBN in_IN 10_CD ×_NN 10_CD ×_NN 5_CD mm_NN vinyl_NN
          specimen_NN molds_NNS (_( Tissue-_NNP Tek_NNP Cryomold_NNP Biopsy_NNP ,_, Miles_NNP Inc_NNP ._.
          Diagnostic_NNP Division_NNP ,_, Elkhart_NNP ,_, IN_IN )_) and_CC embedded_VBN in_IN O_NNP ._. C_NNP ._. T_NN ._.
          compound_NN (_( Miles_NNP )_) ._. The_DT molds_NNS with_IN specimens_NNS were_VBD frozen_VBN in_IN
          liquid_JJ nitrogen_NN and_CC stored_VBD at_IN -_: 80_CD °_NN C_NNP until_IN use_NN ._. Frozen_NNP
          tissues_NNS were_VBD sliced_JJ into_IN 7_CD μm_NN serial_NN sections_NNS using_VBG a_DT
          cryostat_NN microtome_NN with_IN specimen_NN retraction_NN during_IN return_NN
          travel_NN (_( Carl_NNP Zeiss_NNP Microm_NNP HM_NNP 505_CD E_NNP ;_: MICROM_NNP Laborgeräte_NNP
          GmbH_NNP ,_, Waldorf_NNP ,_, Germany_NNP )_) ._. The_DT slides_NNS were_VBD dried_VBN overnight_JJ
          at_IN room_NN temperature_NN and_CC stored_VBD at_IN 4_CD °_NN C_NNP ._. The_DT
          immunohistochemical_JJ and_CC histochemical_JJ procedures_NNS were_VBD
          performed_VBN within_IN two_CD weeks_NNS ._. If_IN required_VBN ,_, additional_JJ
          sections_NNS were_VBD obtained_VBN from_IN frozen_VBN blocks_NNS ._.
          The_DT labeled_VBN streptavidin-biotin_JJ method_NN was_VBD employed_VBN
          for_IN peroxidase_NN immunohistochemistry_NN ._. All_DT steps_NNS were_VBD
          performed_VBN at_IN room_NN temperature_NN ._. Universal_NNP DAKO_NNP LSAB_NNP ®_NN 2_CD
          Peroxidase_NNP Kit_NNP (_( DAKO_NNP Corporation_NNP ,_, Carpinteria_NNP ,_, CA_NNP )_) was_VBD
          used_VBN according_VBG to_TO the_DT instructions_NNS provided_VBN by_IN vendor_NN
          with_IN some_DT modifications_NNS ._. Briefly_NNP ,_, cryostat_NN sections_NNS were_VBD
          fixed_VBN with_IN acetone_NN ,_, dried_VBD for_IN 30_CD minutes_NNS ,_, and_CC rinsed_JJ in_IN
          phosphate_NN buffered_JJ saline_NN (_( PBS_NNP )_) ._. Phosphate_NNP buffered_JJ
          saline_NN was_VBD freshly_RB prepared_VBN before_IN staining_VBG from_IN frozen_VBN
          10_CD ×_NN stock_NN solution_NN ,_, and_CC pH_NN adjusted_VBN to_TO 7_CD ._. 22_CD ._. Mouse_NNP
          primary_JJ antibody_NN ,_, negative_JJ control_NN reagent_NN (_( DAKO_NNP )_) ,_, or_CC PBS_NNP
          were_VBD applied_VBN for_IN 15_CD minutes_NNS ._. Slides_NNS were_VBD washed_VBN twice_RB in_IN
          PBS_NNP ,_, and_CC link_NN solution_NN (_( biotinated_JJ anti-mouse_JJ antibody_NN )_)
          was_VBD applied_VBN for_IN 15_CD minutes_NNS ._. Subsequently_RB ,_, washed_VBN slides_NNS
          were_VBD incubated_JJ with_IN streptavidin-peroxidase_JJ conjugate_NN for_IN
          15_CD minutes_NNS ,_, washed_VBD again_RB ,_, and_CC incubated_JJ 5_CD minutes_NNS in_IN
          substrate-chromogen_JJ solution_NN ,_, rinsed_JJ with_IN PBS_NNP ,_, washed_VBN in_IN
          distilled_VBN water_NN ,_, counterstained_JJ 2_CD minutes_NNS with_IN Harris_NNP
          hematoxylin_NN diluted_VBD 1_CD :_: 20_CD ,_, dehydrated_JJ ,_, and_CC mounted_VBD ._.
          Purified_NNP mouse_NN monoclonal_NN antibody_NN to_TO p_NN 27_CD cell_NN cycle_NN
          inhibitor_NN protein_NN ,_, clone_NN G_NNP 173_CD -_: 524_CD ,_, was_VBD purchased_VBN from_IN
          PharMingen_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP ,_, and_CC used_VBD at_IN dilution_NN 1_CD :_: 50_CD ._.
          This_DT antibody_NN shows_VBZ a_DT single_JJ band_NN in_IN western_JJ blots_NNS (_( Fig_NNP ._.
          2_LS )_) ._. Other_JJ primary_JJ antibodies_NNS used_VBN in_IN some_DT instances_NNS (_( Fig_NNP ._.
          10_CD )_) were_VBD mouse_NN monoclonal_NN antibodies_NNS to_TO cyclin_NN D_NNP 1_CD (_( cD_NN 1_CD ,_,
          clone_NN DCS-_NNP 6_CD ,_, diluted_VBD 1_CD :_: 20_CD ,_, NeoMarkers_NNP ,_, Fremont_NNP ,_, CA_NNP )_) ,_,
          cyclin_NN E_NNP (_( cE_NN ,_, HE_PRP 111_CD ,_, 1_CD :_: 40_CD ,_, Santa_NNP Cruz_NNP Biotechnology_NNP ,_,
          Santa_NNP Cruz_NNP ,_, CA_NNP )_) ,_, Ki_NNP 67_CD (_( Ki-_NNP 67_CD ,_, 1_CD :_: 50_CD ,_, Dako_NNP Corporation_NNP ,_,
          Carpinteria_NNP ,_, CA_NNP )_) ,_, p_NN 21_CD Cip_NNP 1_CD /_NN WAF_NNP 1_CD (_( p_NN 21_CD ,_, clone_NN 70_CD ,_, 1_CD :_: 25_CD ,_,
          Transduction_NNP Laboratories_NNPS ,_, San_NNP Diego_NNP ,_, CA_NNP )_) ,_, and_CC
          retinoblastoma_NN protein_NN (_( pRb_NN ,_, 05_CD -_: 218_CD ,_, 1_CD :_: 50_CD ,_, Upstate_NNP
          Biotechnology_NNP ,_, Lake_NNP Placid_NNP ,_, NY_NNP )_) ._.
        
        
          Histochemistry_NNP
          To_TO determine_VB a_DT character_NN of_IN muscle_NN fibers_NNS (_( type_NN II_NNP or_CC
          type_NN I_PRP )_) exhibiting_VBG changes_NNS in_IN p_NN 27_CD expression_NN ,_, adjacent_JJ
          cryostat_NN sections_NNS were_VBD stained_JJ for_IN actomyosin_NN
          adenosinetriphosphatase_NN (_( ATPase_NNP )_) ._. The_DT procedure_NN for_IN the_DT
          histochemical_JJ demonstration_NN of_IN actomyosin_NN ATPase_NNP was_VBD
          employed_VBN as_IN described_VBN by_IN Goth_NNP and_CC Samara_NNP [_NN 24_CD ]_NN ._.
          Briefly_NNP ,_, fixed_VBN sections_NNS were_VBD washed_VBN in_IN rinse_NN solution_NN [_NN 18_CD
          mM_NN calcium_NN chloride_NN in_IN 100_CD mM_NN tris_NNS (_( hydroxymethyl_NN )_)
          aminomethane_NN (_( Tris_NNP )_) ,_, pH_NN 7_CD ._. 8_CD ]_NN for_IN 1_CD minute_NN ,_, preincubated_JJ
          either_CC in_IN 50_CD mM_NN potassium_NN acetate_NN in_IN 18_CD mM_NN calcium_NN
          chloride_NN at_IN pH_NN 4_CD ._. 35_CD (_( for_IN acid-stable_JJ myosin_NN ATPase_NNP ,_, type_NN
          I_PRP slow_JJ twitch_VB muscle_NN fibers_NNS )_) ,_, or_CC in_IN 18_CD mM_NN calcium_NN
          chloride_NN in_IN 100_CD mM_NN 2_CD -_: amino-_NN 2_CD -_: methyl-_NN 1_CD -_: propanol_NN at_IN pH_NN 10_CD ._. 4_LS
          (_( for_IN alkali-stable_JJ myosin_NN ATPase_NNP ,_, type_NN II_NNP fast_RB twitch_VB
          fibers_NNS )_) ._. All_DT sections_NNS were_VBD washed_VBN in_IN rinse_NN solution_NN ,_, then_RB
          incubated_JJ at_IN 37_CD °_NN C_NNP in_IN solution_NN containing_VBG 2_CD ._. 7_CD mM_NN ATP_NNP ,_, 50_CD
          mM_NN potassium_NN chloride_NN and_CC 18_CD mM_NN calcium_NN chloride_NN in_IN 100_CD
          mM_NN 2_CD -_: amino-_NN 2_CD -_: methyl-_NN 1_CD -_: propanol_NN at_IN pH_NN 9_CD ._. 4_CD for_IN 30_CD minutes_NNS ,_,
          and_CC washed_VBD in_IN 1_CD %_NN calcium_NN chloride_NN ._. The_DT sections_NNS were_VBD
          placed_VBN in_IN 2_CD %_NN cobalt_NN chloride_NN solution_NN for_IN 3_CD minutes_NNS ,_,
          washed_VBN in_IN four_CD 30_CD -_: sec_NN changes_NNS in_IN 100_CD mM_NN
          2_CD -_: amino-_NN 2_CD -_: methyl-_NN 1_CD -_: propanol_NN at_IN pH_NN 9_CD ._. 4_CD ,_, developed_VBN in_IN 1_CD %_NN
          ammonium_NN sulfide_NN solution_NN for_IN 3_CD minutes_NNS ,_, washed_VBN in_IN
          running_VBG tap_VB water_NN for_IN 5_CD minutes_NNS ,_, dehydrated_JJ in_IN graded_JJ
          ethanol_NN ,_, cleared_VBD in_IN xylene_NN and_CC mounted_VBD in_IN Canada_NNP balsam_NN ._.
          All_DT chemicals_NNS were_VBD obtained_VBN from_IN Sigma_NNP Chemical_NNP Co_NNP ._. ,_, St_NNP
          Louis_NNP ,_, MO_NNP ._.
        
        
          Western_JJ blots_NNS
          For_IN preparation_NN of_IN protein_NN lysates_NNS from_IN tissue_NN samples_NNS
          (_( levator_NN ani_NN muscle_NN ;_: rectus_JJ fascia_NN =_SYM ~_NN negative_JJ control_NN ;_:
          and_CC whole_JJ placenta_NN =_SYM low_JJ p_NN 27_CD positive_JJ control_NN )_) 100_CD tissue_NN
          sections_NNS (_( 7_CD μm_NN thick_JJ )_) were_VBD collected_VBN into_IN microcentrifuge_NN
          tubes_NNS and_CC lysed_JJ by_IN adding_VBG ice-cold_JJ lysis_NNS buffer_NN (_( 20_CD mM_NN
          Tris_NNP pH_NN 7_CD ._. 5_CD ,_, 200_CD mM_NN NaCI_NNP ,_, 0_CD ._. 25_CD %_NN Nonidet_NNP P-_NNP 40_CD )_) containing_VBG 1_CD
          mM_NN sodium_NN orthovanadate_NN ,_, 10_CD mM_NN sodium_NN fluoride_NN ,_, and_CC 1_CD mM_NN
          phenylmethylsulfonyl_NN fluoride_NN (_( 400_CD μl_NN /_NN 100_CD mg_NN of_IN tissue_NN
          sections_NNS )_) ._. After_IN 15_CD min_NN on_IN ice_NN ,_, the_DT lysates_NNS were_VBD
          sonicated_JJ by_IN Sonicator_NNP ™_NN Cell_NNP Disruptor_NNP (_( Heat_NNP
          Systems-_NNP Ultrasonic_NNP ,_, Inc_NNP ._. ,_, Plainview_NNP ,_, NY_NNP )_) for_IN 5_CD seconds_NNS ,_,
          and_CC centrifuged_JJ at_IN 11000_CD ×_NN 
          g_SYM for_IN 10_CD min_NN at_IN 4_CD °_NN C_NNP ._. Supernatants_NNP
          were_VBD stored_VBN at_IN -_: 80_CD °_NN C_NNP ._. We_PRP also_RB prepared_VBD cell_NN lysates_NNS from_IN
          primary_JJ trophoblast_NN cultures_NNS (_( =_SYM high_JJ p_NN 27_CD positive_JJ
          control_NN )_) ,_, which_WDT were_VBD established_VBN and_CC processed_VBN as_IN
          described_VBN previously_RB [_NN 18_CD ]_NN ._.
          Protein_NNP concentrations_NNS were_VBD determined_VBN by_IN Bradford_NNP
          assay_NN (_( Bio-_NNP Rad_NNP ,_, Hercules_NNP ,_, CA_NNP )_) ._. Equal_NNP amounts_NNS of_IN protein_NN
          (_( 21_CD μg_NN ;_: without_IN boiling_VBG )_) were_VBD loaded_VBN onto_IN reducing_VBG 10_CD %_NN
          SDS-Tris-glycine_NNP polyacrylamide_NN gels_NNS and_CC transferred_VBN to_TO
          nitrocellulose_NN (_( Bio-_NNP Rad_NNP )_) ._. For_IN this_DT study_NN ,_, the_DT first_JJ five_CD
          lanes_NNS were_VBD loaded_VBN with_IN following_JJ lysates_NNS :_: Lane_NNP 1_CD =_SYM whole_JJ
          placenta_NN (_( WP_NNP ,_, Fig_NNP ._. 2_LS )_) ,_, lane_NN 2_CD =_SYM trophoblast_NN cultured_JJ for_IN
          120_CD hours_NNS (_( TrC_NNP )_) and_CC derived_VBN from_IN the_DT placenta_NN loaded_VBN in_IN
          lane_NN 1_CD ,_, lane_NN 3_CD =_SYM rectus_JJ fascia_NN (_( RF_NNP )_) ,_, lane_NN 4_CD =_SYM levator_NN
          muscle_NN from_IN symptomatic_JJ female_NN ,_, age_NN 63_CD (_( sLM_NN )_) ,_, and_CC lane_NN 5_CD
          =_SYM levator_NN muscle_NN from_IN asymptomatic_JJ female_JJ (_( aLM_NN )_) ._.
          Remaining_VBG 5_CD lanes_NNS were_VBD loaded_VBN with_IN molecular_JJ weight_NN
          markers_NNS ,_, and_CC sLM_NN ,_, aLM_NN ,_, TrC_NNP and_CC WP_NNP lysates_NNS ._. After_IN
          transfer_NN ,_, the_DT membrane_NN was_VBD cut_VBN in_IN two_CD pieces_NNS ,_, just_RB in_IN the_DT
          front_NN of_IN the_DT molecular_JJ weight_NN markers_NNS ._. Membranes_NNP were_VBD
          washed_VBN in_IN Tris-buffered_NNP saline_NN containing_VBG 0_CD ._. 05_CD %_NN Tween_NNP 20_CD
          (_( 
          TBST_NNP )_) and_CC non-specific_JJ binding_JJ sites_NNS
          were_VBD blocked_VBN by_IN immersing_VBG the_DT membrane_NN in_IN blocking_VBG
          reagent_NN (_( 0_CD ._. 5_LS %_NN casein_NN in_IN TBST_NNP )_) for_IN 1_CD hour_NN at_IN room_NN
          temperature_NN on_IN an_DT orbital_NN shaker_NN ._. After_IN blocking_VBG ,_, the_DT
          membranes_NNS were_VBD briefly_NN rinsed_JJ in_IN two_CD changes_NNS of_IN TBST_NNP ,_, and_CC
          washed_VBD once_RB for_IN 15_CD minutes_NNS and_CC twice_RB for_IN 5_CD minutes_NNS in_IN
          fresh_JJ changes_NNS of_IN TBST_NNP ._. Membrane_NNP with_IN first_JJ five_CD lanes_NNS was_VBD
          stained_JJ for_IN p_NN 27_CD (_( 0_CD ._. 1_LS μg_NN /_NN ml_NN in_IN blocking_VBG reagent_NN ,_, clone_NN
          G_NNP 173_CD -_: 524_CD ,_, PharMingen_NNP )_) overnight_JJ at_IN 4_CD °_NN C_NNP on_IN an_DT orbital_NN
          shaker_NN ,_, followed_VBN by_IN secondary_JJ antibody_NN (_( see_VB below_IN )_) ._. After_IN
          development_NN and_CC film_NN exposure_NN ,_, the_DT membrane_NN was_VBD washed_VBN
          and_CC stained_JJ for_IN actin_NN (_( 0_CD ._. 25_CD μg_NN /_NN ml_NN in_IN blocking_VBG reagent_NN ,_,
          clone_NN C_NNP 4_CD ,_, Boehringer_NNP Mannheim_NNP Corp_NNP ._. ,_, Indianapolis_NNP ,_, IN_IN )_) ._.
          Remaining_VBG piece_NN of_IN membrane_NN was_VBD processed_VBN with_IN control_NN
          staining_VBG (_( blocking_VBG reagent_NN overnight_JJ at_IN 4_CD °_NN C_NNP on_IN an_DT orbital_NN
          shaker_NN ,_, followed_VBN by_IN secondary_JJ antibody_NN )_) ._. After_IN overnight_JJ
          incubation_NN ,_, membranes_NNS were_VBD washed_VBN and_CC incubated_JJ with_IN
          peroxidase_NN labeled_VBD secondary_JJ antibody_NN (_( goat_NN anti-mouse_JJ
          IgG_NNP and_CC IgM_NNP ,_, pre-absorbed_JJ with_IN human_JJ serum_NN and_CC diluted_VBN 1_CD :_:
          2000_CD ;_: Jackson_NNP Immunoresearch_NNP ,_, West_NNP Grove_NNP ,_, PA_NNP )_) for_IN 1_CD hour_NN
          at_IN room_NN temperature_NN ._. The_DT membranes_NNS were_VBD washed_VBN 1_CD ×_NN 15_CD
          min_NN ,_, 2_CD ×_NN 10_CD min_NN and_CC 4_CD ×_NN 5_CD min_NN in_IN fresh_JJ changes_NNS of_IN TBST_NNP ,_,
          and_CC incubated_JJ for_IN 1_CD hour_NN in_IN blocking_VBG buffer_NN at_IN room_NN
          temperature_NN ._. Bound_NNP antibodies_NNS were_VBD detected_VBN by_IN a_DT
          chemiluminescent_NN detection_NN system_NN (_( ECL_NNP ;_: Amersham_NNP
          Pharmacia_NNP Biotech_NNP ,_, Piscataway_NNP ,_, NJ_NNP )_) as_IN recommended_VBN by_IN the_DT
          manufacturer_NN 's_POS protocol_NN ._. For_IN exposure_NN (_( first_JJ 5_CD min_NN ,_, and_CC
          second_JJ up_IN to_TO 2_CD h_NN )_) we_PRP used_VBD Kodak_NNP XAR_NNP film_NN (_( Eastman_NNP Kodak_NNP ,_,
          Rochester_NNP ,_, NY_NNP )_) ._.
        
        
          Image_NN analysis_NN
          Evaluation_NNP was_VBD performed_VBN on_IN a_DT Leitz_NNP DM_NNP RB_NNP (_( Leica_NNP Inc_NNP ._. ,_,
          Wetzlar_NNP ,_, Germany_NNP )_) microscope_NN equipped_VBN with_IN differential_NN
          interference_NN contrast_NN and_CC a_DT DEI-_NNP 470_CD CCD_NNP Video_NNP Camera_NNP
          System_NNP (_( Optronics_NNP Engineering_NNP ,_, Goleta_NNP ,_, CA_NNP )_) with_IN detail_NN
          enhancement_NN ._. The_DT video_NN images_NNS were_VBD captured_VBN by_IN CG-_NNP 7_CD color_NN
          frame_NN grabber_NN (_( Scion_NNP Corporation_NNP ,_, Frederick_NNP ,_, MD_NNP )_)
          supported_VBN by_IN Scion_NNP Image_NN public_JJ software_NN developed_VBN at_IN the_DT
          National_NNP Institutes_NNPS of_IN Health_NNP (_( Wayne_NNP Rasband_NNP ,_, NIH_NNP ,_,
          Bethesda_NNP ,_, MD_NNP )_) ,_, and_CC ported_JJ to_TO Windows_NNP 98_CD ._. The_DT pictures_NNS
          were_VBD copied_VBN into_IN the_DT Microsoft_NNP ®_NN PowerPoint_NNP ®_NN 97_CD SR-_NNP 2_CD
          (_( Microsoft_NNP Corporation_NNP ,_, Redmont_NNP ,_, WA_NNP )_) software_NN ,_, labeled_VBN ,_,
          and_CC saved_VBD in_IN Portable_NNP Network_NNP Graphics_NNP format_NN ._.
          The_DT immunohistochemical_JJ staining_VBG was_VBD quantified_VBN as_IN an_DT
          area_NN in_IN square_JJ micrometers_NNS (_( maximum_NN area_NN for_IN whole_JJ screen_NN
          was_VBD 307_CD ,_, 200_CD sq_NN micrometers_NNS at_IN 100_CD ×_NN magnification_NN )_)
          occupied_VBN by_IN the_DT densities_NNS of_IN peroxidase_NN staining_VBG above_IN
          the_DT sample_NN background_NN ,_, as_IN described_VBN previously_RB [_NN 25_CD 26_CD ]_NN
          ._. Briefly_NNP ,_, the_DT illumination_NN of_IN empty_JJ field_NN (_( image_NN
          background_NN )_) was_VBD first_RB adjusted_VBN to_TO 40_CD in_IN 0_CD to_TO 255_CD scale_NN ._.
          Measurement_NNP of_IN an_DT area_NN of_IN peroxidase_NN staining_VBG was_VBD
          performed_VBN using_VBG the_DT density_NN slice_NN method_NN ._. The_DT upper_JJ limit_NN
          of_IN the_DT density_NN slice_NN was_VBD set_VBN at_IN the_DT 255_CD (_( maximum_NN density_NN
          value_NN )_) and_CC the_DT lower_JJR limit_NN at_IN 150_CD ,_, sufficiently_RB high_JJ
          above_IN the_DT hematoxylin_NN staining_VBG of_IN the_DT nuclei_NN ,_, which_WDT does_VBZ
          not_RB exceed_VB a_DT density_NN value_NN 120_CD ._. Under_IN these_DT conditions_NNS ,_,
          the_DT measured_VBN area_NN represented_VBD a_DT crude_NN value_NN in_IN square_JJ
          micrometers_NNS (_( e_SYM ._. g_SYM ._. ,_, 50_CD ,_, 000_CD )_) ._. To_TO obtain_VB net_JJ values_NNS ,_, each_DT
          crude_NN value_NN was_VBD subtracted_VBN with_IN the_DT value_NN of_IN tissue_NN
          background_NN obtained_VBN from_IN the_DT same_JJ sample_NN stained_JJ with_IN a_DT
          control_NN staining_VBG (_( e_SYM ._. g_SYM ._. ,_, 500_CD μm_NN 2_CD ,_, net_JJ value_NN =_SYM 49_CD ,_, 500_CD μm_NN
          2_LS )_) ._. Six_CD measurements_NNS were_VBD performed_VBN on_IN each_DT biopsy_NN
          sample_NN ._. These_DT six_CD values_NNS represented_VBD a_DT dataset_NN for_IN a_DT
          single_JJ biopsy_NN (_( patient_NN )_) stained_JJ for_IN a_DT particular_JJ marker_NN ._.
          Data_NNS in_IN Fig_NNP ._. 7_CD represent_VB means_NNS of_IN 54_CD measurements_NNS from_IN
          asymptomatic_JJ patients_NNS (_( A_DT ;_: 
          n_NN =_SYM 9_CD )_) and_CC 132_CD measurements_NNS from_IN
          symptomatic_JJ patients_NNS (_( S_NNP ;_: 
          n_NN =_SYM 22_CD )_) ._.
          To_TO evaluate_VB the_DT density_NN of_IN p_NN 27_CD staining_VBG in_IN western_JJ
          blots_NNS ,_, we_PRP used_VBD a_DT different_JJ approach_NN ._. Scanned_NNP blot_NN was_VBD
          transferred_VBN into_IN the_DT Scion_NNP Image_NN ,_, enlarged_JJ 4_CD ×_NN (_( two_CD times_NNS
          2_CD ×_NN )_) and_CC each_DT lane_NN was_VBD processed_VBN as_IN follows_VBZ ._. Small_JJ square_JJ
          area_NN (_( 20_CD ×_NN 20_CD pixels_NNS )_) was_VBD used_VBN to_TO obtain_VB six_CD background_NN
          measurements_NNS above_IN the_DT p_NN 27_CD band_NN ._. Subsequently_RB ,_, six_CD
          measurements_NNS of_IN staining_VBG within_IN the_DT p_NN 27_CD band_NN (_( crude_NN
          values_NNS )_) were_VBD obtained_VBN ._. Each_DT crude_NN value_NN was_VBD subtracted_VBN
          with_IN corresponding_JJ background_NN value_NN ,_, giving_VBG the_DT six_CD net_JJ
          values_NNS of_IN p_NN 27_CD density_NN ._. The_DT net_JJ values_NNS were_VBD used_VBN for_IN
          statistical_JJ calculations_NNS ._.
        
        
          Statistical_NNP analysis_NN
          Statistical_NNP analysis_NN of_IN data_NNS was_VBD performed_VBN using_VBG the_DT
          Statistical_NNP Package_NNP of_IN the_DT Microsoft_NNP Excel_NNP 97_CD SR-_NNP 2_CD
          (_( Microsoft_NNP Corporation_NNP ,_, Redmont_NNP ,_, WA_NNP )_) professional_JJ version_NN
          (_( Descriptive_NNP Statistics_NNPS )_) ,_, and_CC GraphPad_NNP InStat_NNP (_( GraphPad_NNP
          Software_NNP ,_, Inc_NNP ._. ,_, San_NNP Diego_NNP ,_, CA_NNP ,_, www_NN ._. graphpad_NN ._. com_NN )_)
          software_NN ._. The_DT Mann-_NNP Whitney_NNP Test_NNP was_VBD used_VBN to_TO compare_VB two_CD
          columns_NNS ._. Repeated_NNP Measures_NNS Analysis_NNP of_IN Variance_NNP ,_, followed_VBN
          by_IN the_DT 
          posthoc_NN Student-_NNP Newman-_NNP Keuls_NNP
          Multiple_NNP Comparison_NNP test_NN ,_, was_VBD used_VBN for_IN a_DT comparison_NN of_IN
          multiple_JJ columns_NNS ._. Values_NNP of_IN 
          P_NN <_NN 0_CD ._. 05_CD were_VBD considered_VBN
          significantly_RB different_JJ ._. Power_NN calculations_NNS were_VBD
          performed_VBN using_VBG GraphPad_NNP StatMate_NNP version_NN 1_CD ._. 01_CD i_NNP (_( GraphPad_NNP
          Software_NNP )_) ._. A_DT threshold_NN 
          P_NN value_NN (_( alpha_NN )_) of_IN 0_CD ._. 05_CD ,_, two_CD
          tailed_JJ ,_, was_VBD selected_VBN ._.
        
      
      
        Results_NNS and_CC Discussion_NNP
        
          Western_JJ blot_NN analysis_NN
          Fig_NNP ._. 2_LS Ashows_NNP that_IN the_DT antibody_NN to_TO p_NN 27_CD ,_, clone_NN G_NNP 173_CD -_: 524_CD ,_,
          produces_VBZ a_DT single_JJ band_NN at_IN 27_CD kDa_NN in_IN all_DT investigated_VBN
          tissues_NNS ,_, and_CC no_DT nonspecific_JJ staining_VBG is_VBZ apparent_JJ with_IN
          secondary_JJ antibody_NN alone_RB ._. This_DT indicates_VBZ that_IN all_DT
          immunohistochemical_JJ observations_NNS should_MD be_VB ascribed_VBN to_TO
          the_DT specific_JJ expression_NN of_IN p_NN 27_CD protein_NN ._. In_IN western_JJ blot_NN ,_,
          the_DT most_RBS prominent_JJ p_NN 27_CD expression_NN was_VBD in_IN the_DT late_JJ
          trophoblast_NN culture_NN (_( 120_CD h_NN )_) ,_, as_IN expected_VBN from_IN our_PRP$
          previous_JJ study_NN [_NN 18_CD ]_NN ._. When_WRB compared_VBN to_TO trophoblast_NN
          culture_NN ,_, the_DT p_NN 27_CD expression_NN in_IN levator_NN ani_NN muscles_NNS was_VBD
          lower_RBR ,_, but_CC higher_JJR then_RB weak_JJ expression_NN in_IN whole_JJ placenta_NN
          and_CC rectus_JJ fascia_NN ._.
          Fig_NNP ._. 2_LS Bshows_NNP quantitative_JJ evaluation_NN (_( materials_NNS and_CC
          methods_NNS )_) of_IN the_DT blot_NN in_IN panel_NN A_DT ._. The_DT statistical_JJ
          evaluation_NN showed_VBD no_DT significant_JJ difference_NN between_IN two_CD
          cases_NNS included_VBD (_( symptomatic_JJ and_CC asymptomatic_JJ female_JJ )_) in_IN
          density_NN of_IN p_NN 27_CD expression_NN in_IN levator_NN ani_NN muscles_NNS ._.
        
        
          Immunohistochemistry_NNP
          Expression_NNP of_IN p_NN 27_CD in_IN levator_NN ani_NN muscle_NN fibers_NNS of_IN
          control_NN asymptomatic_JJ women_NNS was_VBD restricted_VBN to_TO the_DT plasma_NN
          membrane_NN and_CC adjacent_JJ nuclei_NN (_( Fig_NNP ._. 3_LS A_DT ,_, and_CC inset_NN )_) ._. Some_DT
          muscle_NN fibers_NNS close_RB to_TO the_DT levator_NN fascia_NN often_RB showed_VBD
          weak_JJ cytoplasmic_JJ staining_VBG but_CC no_DT change_NN in_IN the_DT cell_NN size_NN
          (_( Fig_NNP ._. 3_LS B_NNP )_) ._. Pre-_NNP and_CC perimenopausal_NN symptomatic_JJ patients_NNS
          showed_VBD hypertrophy_NN of_IN muscle_NN fibers_NNS ,_, and_CC this_DT was_VBD
          associated_VBN with_IN variable_JJ cytoplasmic_JJ p_NN 27_CD expression_NN ,_,
          ranging_VBG from_IN none_NN to_TO moderate_VB (_( Fig_NNP ._. 3_LS C_NNP )_) ._. Biopsy_NNP samples_NNS
          obtained_VBN from_IN symptomatic_JJ women_NNS in_IN advanced_JJ postmenopause_NN
          showed_VBD diminution_NN of_IN size_NN in_IN some_DT fibers_NNS accompanied_VBN by_IN
          strong_JJ cytoplasmic_JJ p_NN 27_CD expression_NN (_( Fig_NNP ._. 3_LS D_NNP ,_, and_CC inset_NN )_) ._.
          This_DT was_VBD accompanied_VBN by_IN appearance_NN of_IN cytoplasmic_JJ
          vacuoles_NNS in_IN regressing_VBG muscle_NN fibers_NNS (_( Fig_NNP ._. 3_LS E_NNP ,_, and_CC inset_NN )_)
          and_CC by_IN an_DT increase_NN in_IN the_DT stromal_NN component_NN (_( s_VBZ ._. Fig_NNP ._.
          3_LS Eand_NNP 3_CD F_NN )_) ._. Control_NN procedure_NN showed_VBD no_DT non-specific_JJ
          staining_VBG (_( inset_NN ._. Fig_NNP ._. 3_LS F_NN )_) ._.
          These_DT data_NNS indicate_VBP that_DT hypertrophy_NN of_IN muscle_NN fibers_NNS
          may_MD be_VB accompanied_VBN by_IN moderate_JJ p_NN 27_CD cytoplasmic_JJ
          expression_NN ._. Further_RB increase_NN in_IN cytoplasmic_JJ staining_VBG (_( p_NN 27_CD
          overexpression_NN )_) accompanies_VBZ shrinking_VBG and_CC fragmentation_NN
          of_IN muscle_NN fibers_NNS ._. This_DT was_VBD characteristic_JJ for_IN symptomatic_JJ
          women_NNS in_IN advanced_JJ postmenopause_NN ,_, suggesting_VBG that_IN hormonal_NN
          changes_NNS accompanying_VBG postmenopause_NN ,_, such_JJ as_IN diminution_NN of_IN
          ovarian_NN sex_NN steroid_NN production_NN ,_, might_MD contribute_VB to_TO the_DT
          degenerative_JJ changes_NNS in_IN the_DT levator_NN ani_NN muscle_NN ._.
          From_IN the_DT ovarian_NN sex_NN steroids_NNS ,_, the_DT role_NN of_IN diminishing_VBG
          estrogen_NN levels_NNS is_VBZ questionable_JJ ,_, since_IN the_DT levator_NN ani_NN
          muscle_NN fibers_NNS do_VBP not_RB express_VB estrogen_NN receptor_NN alpha_NN [_NN 2_CD
          26_CD ]_NN ._. It_PRP is_VBZ not_RB known_VBN if_IN estrogen_NN receptor_NN beta_NN is_VBZ
          expressed_VBN ,_, but_CC levator_NN ani_NN muscle_NN fibers_NNS show_VBP nuclear_JJ
          expression_NN of_IN progesterone_NN and_CC androgen_NN receptors_NNS [_NN 26_CD ]_NN
          ._. Altered_NNP ovarian_NN function_NN in_IN the_DT premenopause_NN can_MD be_VB
          observed_VBN as_RB early_RB as_IN age_NN 43_CD years_NNS ,_, and_CC includes_VBZ
          hyperestrogenism_NN and_CC hypergonadotropism_NN ,_, accompanied_VBN by_IN
          decreased_VBD progesterone_NN secretion_NN [_NN 27_CD ]_NN ._. During_IN the_DT
          transition_NN from_IN pre-_NN to_TO postmenopause_NN both_DT estrogen_NN and_CC
          androgen_NN levels_NNS also_RB decline_VBP [_NN 28_CD ]_NN ._. These_DT hormonal_NN
          alterations_NNS may_MD well_RB be_VB responsible_JJ for_IN the_DT increased_VBN
          gynecological_JJ morbidity_NN that_WDT characterizes_VBZ this_DT period_NN of_IN
          life_NN ,_, including_VBG structural_JJ and_CC molecular_JJ changes_NNS in_IN
          levator_NN ani_NN muscle_NN and_CC increasing_VBG incidence_NN of_IN pelvic_JJ
          floor_NN disorders_NNS ._.
        
        
          Diminution_NNP of_IN fast_RB twitch_VB fibers_NNS
          We_PRP also_RB studied_VBD histochemical_JJ staining_VBG (_( type_NN II_NNP and_CC
          type_NN I_PRP fibers_NNS )_) along_IN with_IN protein_NN p_NN 27_CD expression_NN ._. Fig_NNP ._. 4_LS ,_,
          A_DT ,_, B_NNP ,_, C_NNP ,_, is_VBZ a_DT biopsy_NN from_IN an_DT asymptomatic_JJ women_NNS (_( age_NN 38_CD )_)
          exhibiting_VBG a_DT proportional_JJ number_NN of_IN fast-_NN (_( f_SYM ;_: Fig_NNP ._. 4_LS A_DT )_)
          and_CC slow_JJ twitch_VB fibers_NNS (_( s_VBZ ;_: Fig_NNP ._. 4_LS B_NNP )_) ,_, and_CC strong_JJ surface_NN
          and_CC nuclear_JJ but_CC no_DT cytoplasmic_JJ p_NN 27_CD expression_NN (_( Fig_NNP ._.
          4_LS C_NNP )_) ._.
          Fig_NNP ._. 5_LS is_VBZ from_IN a_DT symptomatic_JJ female_JJ (_( age_NN 50_CD )_) ._. Some_DT
          muscle_NN fibers_NNS exhibited_VBN both_DT type_NN I_PRP and_CC type_NN II_NNP staining_VBG ,_,
          representing_VBG the_DT "_'' transitory_JJ "_'' (_( t_NN 1_CD and_CC t_NN 2_LS )_) types_NNS ._. This_DT was_VBD
          accompanied_VBN by_IN p_NN 27_CD cytoplasmic_JJ expression_NN in_IN t_NN 2_CD fibers_NNS ._.
          In_IN addition_NN ,_, some_DT fibers_NNS showed_VBD type_NN I_PRP staining_VBG
          accompanied_VBN by_IN p_NN 27_CD cytoplasmic_JJ expression_NN (_( t_NN 3_CD fibers_NNS )_) ._.
          This_DT contrasted_VBN with_IN a_DT quiescent_JJ (_( genuine_JJ )_) fast-_NN (_( f_SYM )_) and_CC
          slow_JJ twitch_VB (_( s_VBZ )_) fibers_NNS ,_, which_WDT showed_VBD either_CC type_NN I_PRP or_CC
          type_NN II_NNP staining_VBG and_CC no_DT p_NN 27_CD cytoplasmic_JJ expression_NN ._. The_DT
          "_'' transitory_JJ "_'' fibers_NNS often_RB exhibited_VBN hypertrophy_NN ._.
          Occurrence_NNP of_IN both_DT type_NN II_NNP and_CC type_NN I_PRP staining_VBG in_IN the_DT
          same_JJ striated_JJ muscle_NN fiber_NN has_VBZ not_RB been_VBN described_VBN ._. When_WRB
          using_VBG the_DT term_NN "_'' transitory_JJ "_'' fibers_NNS ,_, we_PRP are_VBP aware_JJ that_IN a_DT
          static_JJ picture_NN can_MD not_RB explain_VB the_DT dynamic_JJ process_NN ._.
          However_RB ,_, the_DT "_'' transitory_JJ "_'' fibers_NNS show_VBP both_DT type_NN II_NNP and_CC
          type_NN I_PRP staining_VBG ,_, cytoplasmic_JJ p_NN 27_CD expression_NN suggestive_JJ of_IN
          ongoing_JJ differentiation_NN [_NN 17_CD 18_CD ]_NN ,_, and_CC marked_VBD
          hypertrophy_NN ._. The_DT occurrence_NN of_IN "_'' transitory_JJ "_'' fibers_NNS was_VBD
          also_RB associated_VBN with_IN a_DT decline_NN in_IN the_DT number_NN of_IN fibers_NNS
          exhibiting_VBG the_DT type_NN II_NNP staining_VBG only_RB ,_, which_WDT suggests_VBZ a_DT
          type_NN II_NNP into_IN type_NN I_PRP transition_NN ._. Also_RB ,_, a_DT lack_NN of_IN muscle_NN
          cell_NN shrinking_NN and_CC fragmentation_NN during_IN this_DT process_NN
          indicates_VBZ that_DT type_NN II_NNP fibers_NNS do_VBP not_RB degenerate_VB but_CC are_VBP
          transformed_VBN into_IN the_DT type_NN I_PRP fibers_NNS ._.
        
        
          Shrinking_VBG and_CC fragmentation_NN of_IN muscle_NN fibers_NNS
          Fig_NNP ._. 6_CD Ashows_NNP a_DT lack_NN of_IN type_NN II_NNP fibers_NNS in_IN
          postmenopausal_NN patient_NN (_( age_NN 63_CD )_) ._. Type_NNP I_PRP staining_VBG was_VBD
          characteristic_JJ for_IN all_DT fibers_NNS present_JJ ,_, including_VBG those_DT
          exhibiting_VBG a_DT diminution_NN in_IN size_NN (_( Fig_NNP ._. 6_CD B_NNP )_) ._. Staining_NNP for_IN
          p_NN 27_CD revealed_VBD appearance_NN of_IN weak_JJ (_( a_DT 1_LS )_) to_TO moderate_VB
          cytoplasmic_JJ expression_NN (_( a_DT 2_LS )_) in_IN some_DT otherwise_RB normal_JJ
          fibers_NNS ._. Very_RB strong_JJ p_NN 27_CD expression_NN was_VBD characteristic_JJ for_IN
          the_DT fibers_NNS exhibiting_VBG cytoplasmic_JJ vacuolization_NN (_( a_DT 3_CD ,_, see_VBP
          also_RB inset_NN ,_, Fig_NNP ._. 3_LS E_NNP )_) and_CC fragmentation_NN (_( a_DT 4_CD ,_, arrow_NN )_) ,_, i_NNP ._. e_SYM ._. ,_,
          morphologic_JJ features_NNS characteristic_JJ for_IN the_DT cells_NNS
          undergoing_VBG apoptotic_JJ cell_NN death_NN [_NN 29_CD ]_NN ._.
        
        
          Quantitative_NNP evaluation_NN of_IN p_NN 27_CD expression_NN
          Fig_NNP ._. 7_CD Ashows_NNP cumulative_JJ data_NNS on_IN p_NN 27_CD expression_NN in_IN
          levator_NN ani_NN muscle_NN from_IN asymptomatic_JJ and_CC symptomatic_JJ
          patients_NNS ._. The_DT mean_JJ p_NN 27_CD expression_NN in_IN symptomatic_JJ patients_NNS
          (_( age_NN range_NN 38_CD -_: 73_CD years_NNS )_) was_VBD much_RB higher_JJR (_( 
          P_NN <_NN 0_CD ._. 0001_CD )_) when_WRB compared_VBN to_TO
          controls_NNS (_( age_NN range_NN 31_CD -_: 49_CD years_NNS )_) ._. The_DT power_NN for_IN number_NN of_IN
          cases_NNS was_VBD 80_CD %_NN ,_, for_IN number_NN of_IN measurements_NNS 99_CD %_NN ._. However_RB ,_,
          there_EX was_VBD also_RB a_DT highly_RB significant_JJ difference_NN in_IN mean_NN
          age_NN between_IN the_DT groups_NNS (_( Fig_NNP ._. 7_CD B_NNP ;_: P_NN <_NN 0_CD ._. 0001_CD ,_, power_NN
          99_CD %_NN )_) ._. At_IN present_JJ ,_, we_PRP are_VBP not_RB able_JJ to_TO determine_VB if_IN in_IN
          asymptomatic_JJ postmenopausal_NN women_NNS the_DT p_NN 27_CD expression_NN in_IN
          levator_NN ani_NN muscles_NNS also_RB increases_VBZ with_IN age_NN ,_, since_IN
          non-urogynecological_JJ surgery_NN ,_, except_IN cancer_NN (_( excluded_VBN )_) ,_,
          is_VBZ exceptional_JJ in_IN such_JJ cases_NNS ._.
        
        
          p_NN 27_CD cytoplasmic_JJ expression_NN and_CC muscle_NN
          abnormality_NN
          An_DT important_JJ question_NN is_VBZ whether_IN the_DT increase_NN in_IN
          cytoplasmic_JJ p_NN 27_CD expression_NN correlates_NNS with_IN the_DT age_NN of_IN the_DT
          patients_NNS and_CC the_DT severity_NN of_IN the_DT muscle_NN abnormality_NN ._. Fig_NNP ._.
          8_CD shows_VBZ a_DT lack_NN of_IN cytoplasmic_JJ p_NN 27_CD staining_VBG of_IN levator_NN ani_NN
          muscle_NN in_IN another_DT control_NN female_JJ (_( age_NN 42_CD ,_, panel_NN A_DT )_)
          exhibiting_VBG normal_JJ size_NN of_IN muscle_NN fibers_NNS (_( n_NN )_) and_CC high_JJ
          proportion_NN of_IN type_NN II_NNP fibers_NNS (_( panel_NN B_NNP )_) ._. Panels_NNP C_NNP and_CC D_NNP
          show_NN a_DT situation_NN in_IN the_DT youngest_JJS patient_NN from_IN symptomatic_JJ
          group_NN (_( age_NN 38_CD ;_: pelvic_JJ organ_NN prolapse_NN )_) ._. The_DT muscle_NN fibers_NNS
          show_NN marked_VBD hypertrophy_NN (_( h_NN )_) and_CC cytoplasmic_JJ p_NN 27_CD
          expression_NN (_( panel_NN C_NNP )_) associated_VBN with_IN a_DT lack_NN of_IN type_NN II_NNP
          staining_VBG (_( panel_NN D_NNP )_) ._. On_IN the_DT other_JJ hand_NN ,_, panels_NNS E_NNP and_CC F_NN
          show_NN a_DT situation_NN in_IN the_DT oldest_JJS female_JJ in_IN asymptomatic_JJ
          group_NN ._. The_DT size_NN of_IN fibers_NNS is_VBZ normal_JJ ,_, but_CC moderate_JJ p_NN 27_CD
          cytoplasmic_JJ staining_VBG is_VBZ evident_JJ (_( panel_NN E_NNP )_) ._. This_DT is_VBZ ,_,
          however_RB ,_, accompanied_VBN by_IN a_DT lack_NN of_IN fast_RB twitch_VB fibers_NNS
          (_( panel_NN F_NN )_) ._.
          Hence_RB ,_, even_RB in_IN the_DT presence_NN of_IN moderate_JJ cytoplasmic_JJ
          p_NN 27_CD expression_NN in_IN muscle_NN fibers_NNS of_IN normal_JJ size_NN (_( Fig_NNP ._. 8_CD E_NNP )_) ,_,
          which_WDT accompanies_VBZ depletion_NN of_IN fast_RB twitch_VB fibers_NNS (_( panel_NN
          F_NN )_) ,_, the_DT woman_NN may_MD remain_VB continent_NN ,_, without_IN an_DT actual_JJ
          evidence_NN of_IN pelvic_JJ floor_NN disorder_NN ._. On_IN the_DT other_JJ hand_NN ,_,
          cytoplasmic_JJ p_NN 27_CD expression_NN accompanying_VBG hypertrophy_NN of_IN
          muscle_NN cells_NNS (_( panel_NN C_NNP )_) was_VBD accompanied_VBN by_IN PFD_NNP ._. These_DT
          observations_NNS indicate_VBP that_IN an_DT increase_NN in_IN cytoplasmic_JJ p_NN 27_CD
          staining_VBG may_MD accompany_VB normal_JJ female_JJ aging_NN (_( age_NN 49_CD )_) ,_,

          along_IN with_IN the_DT diminution_NN of_IN fast_RB twitch_VB fibers_NNS in_IN
          otherwise_RB normal_JJ muscles_NNS ,_, and_CC without_IN manifestation_NN of_IN
          PFD_NNP ._. Conversely_RB ,_, levator_NN ani_NN from_IN younger_JJR symptomatic_JJ
          patient_NN (_( age_NN 38_CD )_) exhibited_VBN hypertrophy_NN of_IN muscle_NN cells_NNS ,_,
          accompanied_VBN by_IN increased_VBN cytoplasmic_JJ p_NN 27_CD expression_NN and_CC
          manifestation_NN of_IN PFD_NNP ._. Altogether_RB ,_, the_DT cytoplasmic_JJ p_NN 27_CD
          expression_NN is_VBZ indicative_JJ of_IN fast_RB to_TO slow_VB twitch_VB
          transition_NN of_IN levator_NN ani_NN myotubes_NNS ,_, but_CC not_RB necessarily_RB
          indicative_JJ of_IN manifestation_NN of_IN PFD_NNP ,_, assuming_VBG normal_JJ
          muscle_NN morphology_NN ._.
          Table_NNP 1_CD summarizes_NNS our_PRP$ observations_NNS ,_, and_CC suggests_VBZ
          possible_JJ pathways_NNS for_IN the_DT transition_NN of_IN type_NN II_NNP to_TO type_NN I_PRP
          fibers_NNS and_CC progression_NN of_IN degeneration_NN of_IN levator_NN ani_NN
          muscle_NN cells_NNS ._. Note_VB that_IN a_DT lack_NN of_IN type_NN I_PRP staining_VBG is_VBZ
          characteristic_JJ for_IN fast_RB twitch_VB fibers_NNS only_RB (_( row_NN 1_LS )_) ,_, and_CC a_DT
          lack_NN of_IN p_NN 27_CD cytoplasmic_JJ expression_NN is_VBZ characteristic_JJ for_IN
          the_DT "_'' resting_VBG "_'' fast-_NN and_CC slow_JJ twitch_VB fibers_NNS and_CC fibers_NNS in_IN
          "_'' early_JJ transition_NN "_'' (_( rows_NNS 1_CD ,_, 2_CD and_CC 5_LS )_) ._. Only_RB fibers_NNS in_IN row_NN
          3_CD show_NN type_NN II_NNP ,_, type_NN I_PRP and_CC p_NN 27_CD cytoplasmic_JJ staining_VBG ,_, and_CC
          a_DT lack_NN of_IN type_NN II_NNP staining_VBG is_VBZ apparent_JJ from_IN row_NN 4_CD on_IN ._.
          During_IN transition_NN ,_, the_DT fast_RB twitch_VB fibers_NNS may_MD increase_VB in_IN
          size_NN ,_, and_CC gradually_RB change_VB into_IN the_DT slow_JJ twitch_VB fibers_NNS
          exhibiting_VBG regular_JJ size_NN ._. Fibers_NNP in_IN "_'' advanced_VBD transition_NN "_''
          (_( rows_NNS 3_CD and_CC 4_LS )_) ,_, and_CC those_DT undergoing_VBG degeneration_NN (_( rows_NNS 6_CD
          and_CC 7_CD )_) ,_, are_VBP associated_VBN with_IN cytoplasmic_JJ p_NN 27_CD expression_NN ._.
          Although_IN rows_NNS 4_CD and_CC 6_CD are_VBP similar_JJ ,_, the_DT latter_NN is_VBZ
          associated_VBN with_IN the_DT regression_NN of_IN many_JJ accompanying_VBG
          myotubes_NNS (_( see_VB Fig_NNP ._. 3_LS ,_, D-F_NNP ,_, and_CC Fig_NNP ._. 6_CD )_) ._.
        
        
          How_WRB unique_JJ is_VBZ the_DT unusual_JJ p_NN 27_CD expression_NN for_IN the_DT
          skeletal_NN muscle_NN ?_.
          p_NN 27_CD is_VBZ a_DT cyclin-dependent_JJ kinase_NN (_( cdk_NN )_) inhibitor_NN ,_, and_CC
          is_VBZ normally_RB expected_VBN to_TO be_VB localized_VBN to_TO the_DT cell_NN nucleus_NN ._.
          In_IN normal_JJ cells_NNS ,_, p_NN 27_CD is_VBZ sequestered_VBN and_CC its_PRP$ activity_NN
          gradually_RB decreases_VBZ as_IN cells_NNS reach_VBP S_NNP phase_NN ,_, p_NN 27_CD
          preferentially_RB binds_NNS cyclin_NN D-_NNP cdk_NN 4_CD ,_, but_CC lower_JJR levels_NNS of_IN
          cdk_NN 4_CD (_( in_IN TGF-β_NNP treated_VBD cells_NNS )_) allow_VB p_NN 27_CD to_TO be_VB available_JJ
          for_IN binding_VBG to_TO the_DT cyclin_NN E-_NNP cdk_NN 2_CD and_CC cyclin_NN A-_NNP cdk_NN 2_CD ._. p_NN 27_CD
          is_VBZ structurally_RB related_VBN to_TO the_DT p_NN 21_CD ,_, having_VBG a_DT similar_JJ
          sequence_NN in_IN the_DT N-_NNP terminal_NN region_NN ._. Inhibition_NNP of_IN cell_NN
          cycle_NN by_IN p_NN 27_CD and_CC p_NN 21_CD is_VBZ complemented_JJ by_IN retinoblastoma_NN
          protein_NN pRb_NN ,_, and_CC other_JJ cell_NN cycle_NN inhibitors_NNS (_( tumor_NN
          suppressor_NN proteins_NNS )_) [_NN 30_CD 31_CD 32_CD ]_NN ._. In_IN reality_NN ,_, besides_IN
          their_PRP$ role_NN in_IN the_DT regulation_NN of_IN the_DT cell_NN cycle_NN ,_, the_DT cdk_NN
          inhibitors_NNS ,_, in_IN association_NN with_IN D-_NNP type_NN cyclins_NNS ,_, cyclin_NN E_NNP ,_,
          and_CC cdk_NN 2_CD ,_, play_VBP a_DT direct_JJ role_NN in_IN the_DT stimulation_NN of_IN
          epithelial_NN cell_NN differentiation_NN [_NN 33_CD ]_NN ._. p_NN 27_CD is_VBZ also_RB
          transiently_RB expressed_VBD in_IN developing_VBG myotomes_NNS and_CC enhances_VBZ
          myogenesis_NNS [_NN 34_CD ]_NN ._.
          The_DT localization_NN of_IN p_NN 27_CD to_TO plasma_NN membrane_NN and_CC the_DT
          cytoplasm_NN in_IN normal_JJ and_CC abnormal_JJ striated_JJ muscle_NN 
          in_IN vivo_NN raises_VBZ a_DT question_NN how_WRB
          unique_JJ these_DT unusual_JJ expressions_NNS are_VBP for_IN the_DT skeletal_NN
          muscle_NN cells_NNS ._. The_DT observations_NNS ,_, summarized_VBD in_IN Table_NNP 1_CD ,_,
          indicate_VBP that_IN cytoplasmic_JJ expression_NN of_IN p_NN 27_CD is_VBZ related_VBN to_TO
          two_CD dynamic_JJ processes_NNS ,_, (_( i_NNP )_) advanced_VBD "_'' transition_NN "_'' of_IN fast_RB
          to_TO slow_VB twitch_VB fibers_NNS (_( rows_NNS 3_CD and_CC 4_CD ,_, Table_NNP 1_LS )_) ,_, and_CC (_( ii_NN )_)
          gradual_JJ degeneration_NN of_IN muscle_NN cells_NNS (_( rows_NNS 6_CD and_CC 7_CD )_) ._. On_IN
          the_DT other_JJ hand_NN ,_, regardless_RB of_IN the_DT status_NN (_( quiescent_JJ fast_RB
          and_CC slow_JJ twitch_VB fibers_NNS ,_, myotubes_NNS in_IN transition_NN or_CC
          degenerating_VBG )_) the_DT muscle_NN cells_NNS exhibit_NN plasma_NN membrane_NN
          p_NN 27_CD staining_VBG ._.
          Excellent_NNP models_NNS for_IN the_DT studies_NNS of_IN cell_NN
          differentiation_NN 
          in_IN vivo_NN are_VBP stratified_JJ squamous_JJ
          epithelia_NN [_NN 35_CD ]_NN ,_, particularly_RB those_DT that_WDT are_VBP easily_RB to_TO
          collect_VB ,_, such_JJ as_IN the_DT samples_NNS of_IN epithelium_NN of_IN ectocervix_NN
          from_IN hysterectomy_NN specimens_NNS ._. In_IN addition_NN ,_, the_DT epithelium_NN
          of_IN ectocervix_NN is_VBZ hormonally_RB dependent_JJ ,_, and_CC shows_VBZ certain_JJ
          changes_NNS along_IN with_IN the_DT fluctuations_NNS of_IN levels_NNS of_IN ovarian_NN
          steroids_NNS during_IN the_DT menstrual_JJ cycle_NN ._. Another_DT ,_, even_RB more_RBR
          hormonally_RB dependent_JJ tissue_NN is_VBZ endometrium_NN ._. Fig_NNP ._. 9_CD shows_VBZ
          p_NN 27_CD expression_NN in_IN the_DT ectocervix_NN and_CC corresponding_JJ
          endometrium_NN (_( from_IN the_DT same_JJ uteri_NN )_) ._.
          In_IN ectocervix_NN ,_, during_IN the_DT early_JJ follicular_NN phase_NN ,_, when_WRB
          increasing_VBG levels_NNS of_IN estrogens_NNS stimulate_VB proliferation_NN of_IN
          stem_NN cells_NNS and_CC subsequent_JJ shift_NN of_IN cells_NNS between_IN the_DT
          layers_NNS -_: toward_IN surface_NN ,_, some_DT mature_VBP epithelial_NN cells_NNS
          (_( upper_JJ intermediate_JJ layers_NNS )_) showed_VBD cytoplasmic_JJ p_NN 27_CD
          staining_VBG (_( white_JJ arrowhead_NN ,_, Fig_NNP ._. 9_CD A_DT )_) ._. p_NN 27_CD expression_NN was_VBD
          also_RB apparent_JJ in_IN the_DT surface_NN (_( degenerating_VBG )_) cells_NNS (_( black_JJ
          arrowhead_NN )_) but_CC not_RB between_IN these_DT two_CD layers_NNS (_( dotted_JJ
          arrowhead_NN )_) ._. This_DT resembles_VBZ the_DT transition_NN of_IN type_NN II_NNP into_IN
          type_NN I_PRP fibers_NNS ,_, and_CC degeneration_NN of_IN myotubes_NNS ._. In_IN the_DT mid_JJ
          follicular_NN phase_NN ,_, p_NN 27_CD staining_VBG was_VBD restricted_VBN to_TO the_DT
          nuclei_NN (_( white_JJ arrow_NN ,_, panel_NN B_NNP )_) ,_, but_CC during_IN the_DT luteal_NN
          phase_NN ,_, when_WRB the_DT influence_NN of_IN estrogens_NNS is_VBZ accompanied_VBN by_IN
          progesterone_NN ,_, the_DT nuclear_JJ p_NN 27_CD diminished_VBN (_( black_JJ arrow_NN ,_,
          panel_NN C_NNP )_) ,_, and_CC mature_VBP and_CC aged_VBN epithelial_NN cells_NNS showed_VBD
          surface_NN p_NN 27_CD expression_NN ,_, similar_JJ to_TO that_DT in_IN all_DT types_NNS of_IN
          muscle_NN fibers_NNS ._.
          In_IN endometrium_NN ,_, the_DT early_JJ follicular_NN phase_NN was_VBD
          associated_VBN with_IN strong_JJ stromal_NN p_NN 27_CD expression_NN (_( s_VBZ ,_, panel_NN
          D_NNP )_) ,_, accompanied_VBN by_IN variable_JJ nuclear_JJ expression_NN in_IN
          epithelium_NN of_IN narrow_JJ glands_NNS (_( arrows_NNS )_) ._. In_IN the_DT mid_JJ
          follicular_NN phase_NN ,_, stromal_NN and_CC nuclear_JJ p_NN 27_CD staining_VBG
          increased_VBN further_JJ (_( panel_NN E_NNP )_) ,_, but_CC luteal_NN phase_NN endometrium_NN
          showed_VBD diminution_NN of_IN both_DT (_( panel_NN F_NN )_) ._. Altogether_RB ,_, these_DT
          observations_NNS indicate_VBP that_IN ,_, in_IN addition_NN to_TO the_DT striated_JJ
          muscle_NN cells_NNS ,_, the_DT cytoplasmic_JJ and_CC plasma_NN membrane_NN p_NN 27_CD
          expression_NN can_MD be_VB observed_VBN (_( under_IN certain_JJ circumstances_NNS )_)
          in_IN other_JJ cell_NN types_NNS ._. Yet_RB ,_, the_DT cytoplasmic_JJ p_NN 27_CD expression_NN
          in_IN abnormal_JJ skeletal_NN muscles_NNS also_RB appears_VBZ to_TO be_VB
          temporary_JJ ,_, i_NNP ._. e_SYM ._. ,_, during_IN the_DT transition_NN (_( type_NN II_NNP to_TO type_NN
          I_PRP )_) and_CC terminal_NN regression_NN of_IN myotubes_NNS ._.
          Moreover_RB ,_, a_DT combined_VBN action_NN of_IN estrogens_NNS and_CC
          progesterone_NN ,_, characteristic_JJ for_IN the_DT luteal_NN phase_NN ,_,
          appears_VBZ to_TO cause_VB a_DT diminution_NN of_IN nuclear_JJ p_NN 27_CD expression_NN
          in_IN the_DT epithelium_NN of_IN ectocervix_NN and_CC endometrium_NN (_( Fig_NNP ._. 9_CD ,_,
          Cand_NNP 9_CD F_NN )_) ._. Curiously_RB ,_, the_DT remnants_NNS of_IN p_NN 27_CD staining_VBG were_VBD
          confined_VBN to_TO the_DT nuclear_JJ envelope_NN (_( arrows_NNS ,_, Fig_NNP ._. 9_CD ,_, Cand_NNP
          9_CD F_NN ;_: see_VB also_RB Fig_NNP ._. 10_CD A_DT )_) ,_, suggesting_VBG a_DT degradation_NN of_IN p_NN 27_CD
          in_IN the_DT nuclear_JJ core_NN ,_, and_CC /_NN or_CC a_DT defect_NN of_IN p_NN 27_CD
          synthesis_NN /_NN transport_NN ._. These_DT tissues_NNS ,_, however_RB ,_, do_VBP posses_NNS
          nuclear_JJ receptors_NNS for_IN both_DT steroids_NNS [_NN 36_CD 37_CD ]_NN ._.
          We_PRP did_VBD not_RB detect_VB similar_JJ fluctuation_NN of_IN nuclear_JJ p_NN 27_CD
          expression_NN in_IN muscle_NN fibers_NNS ,_, yet_RB myotubes_NNS do_VBP not_RB exhibit_VB
          estrogen_NN receptor_NN expression_NN [_NN 2_CD 26_CD ]_NN ._. However_RB ,_,
          estrogen_NN ,_, progesterone_NN and_CC androgen_NN receptors_NNS are_VBP
          expressed_VBN in_IN the_DT principal_JJ cells_NNS (_( fibroblasts_NNS )_) of_IN levator_NN
          ani_NN fascia_NN [_NN 26_CD ]_NN ,_, which_WDT represents_VBZ another_DT important_JJ
          component_NN of_IN the_DT pelvic_JJ floor_NN involved_VBN in_IN its_PRP$ suspensory_NN
          function_NN ,_, and_CC might_MD be_VB a_DT target_NN of_IN the_DT complex_JJ effect_NN of_IN
          hormonal_NN fluctuations_NNS during_IN the_DT cycle_NN ,_, and_CC influenced_VBN by_IN
          the_DT hormone_NN replacement_NN therapy_NN in_IN postmenopausal_NN
          women_NNS ._.
          Some_DT recent_JJ studies_NNS indicate_VBP that_IN long-term_JJ continuous_JJ
          estrogen_NN replacement_NN is_VBZ not_RB beneficial_JJ ,_, yet_RB may_MD worsen_VB or_CC
          induce_VB the_DT manifestation_NN of_IN PFD_NNP [_NN 38_CD 39_CD ]_NN ,_, possibly_RB
          through_IN the_DT suppression_NN of_IN sex_NN steroid_NN receptor_NN
          expression_NN in_IN the_DT pelvic_JJ floor_NN ._. Since_IN progesterone_NN and_CC
          androgen_NN receptors_NNS are_VBP also_RB expressed_VBN in_IN the_DT levator_NN ani_NN
          muscle_NN ,_, and_CC long-term_JJ estrogen_NN replacement_NN therapy_NN
          appears_VBZ to_TO suppress_VB their_PRP$ expression_NN [_NN 26_CD ]_NN ,_, both_DT the_DT
          levator_NN ani_NN fascia_NN and_CC muscle_NN might_MD be_VB affected_VBN by_IN
          continuous_JJ estrogen_NN replacement_NN ._.
        
        
          Correlation_NNP of_IN cytoplasmic_JJ p_NN 27_CD with_IN other_JJ cell_NN
          cycle_NN proteins_NNS
          Cytoplasmic_NNP p_NN 27_CD expression_NN in_IN the_DT skeletal_NN muscle_NN and_CC
          epithelium_NN of_IN ectocervix_NN raises_VBZ the_DT question_NN if_IN it_PRP is_VBZ
          associated_VBN with_IN some_DT other_JJ cell_NN cycle_NN proteins_NNS ,_, which_WDT
          otherwise_RB show_NN characteristic_JJ nuclear_JJ localization_NN ._. We_PRP
          investigated_VBD ovarian_NN CL_NNP ,_, another_DT interesting_JJ structure_NN
          for_IN the_DT studies_NNS of_IN cell_NN differentiation_NN and_CC degeneration_NN 
          in_IN vivo_NN [_NN 21_CD 22_CD 23_CD ]_NN ,_, and_CC found_VBD
          that_IN cytoplasmic_JJ p_NN 27_CD expression_NN is_VBZ constantly_RB present_JJ in_IN
          the_DT CL_NNP of_IN pregnancy_NN ._.
          Fig_NNP ._. 10_CD ,_, panel_NN A_DT ,_, shows_VBZ that_IN the_DT mature_VBP CL_NNP of_IN the_DT
          menstrual_JJ cycle_NN has_VBZ p_NN 27_CD expression_NN limited_VBN to_TO the_DT luteal_NN
          vessels_NNS ;_: luteal_NN cells_NNS show_VBP only_RB traces_VBZ of_IN nuclear_JJ p_NN 27_CD
          (_( arrow_NN )_) and_CC no_DT cytoplasmic_JJ staining_VBG ._. However_RB ,_, in_IN the_DT CL_NNP
          of_IN pregnancy_NN ,_, nuclei_NN of_IN luteal_NN cells_NNS show_VBP abundant_JJ p_NN 27_CD
          expression_NN (_( arrow_NN ,_, panel_NN B_NNP )_) ,_, accompanied_VBN by_IN moderate_JJ
          cytoplasmic_JJ staining_VBG ._. Nuclear_JJ p_NN 27_CD is_VBZ also_RB evident_JJ in_IN
          stromal_NN cells_NNS (_( s_VBZ ,_, arrowhead_NN )_) ._. When_WRB compared_VBN to_TO p_NN 27_CD ,_, the_DT
          cyclin_NN D_NNP 1_CD is_VBZ expressed_VBN in_IN some_DT nuclei_NN of_IN luteal_NN cells_NNS
          only_RB (_( arrow_NN ,_, panel_NN C_NNP )_) and_CC absent_JJ from_IN the_DT stromal_NN cells_NNS
          in_IN the_DT CL_NNP of_IN pregnancy_NN ._. However_RB ,_, the_DT cytoplasmic_JJ
          expression_NN of_IN cyclin_NN D_NNP 1_CD is_VBZ similar_JJ to_TO that_DT of_IN p_NN 27_CD ._.
          Staining_NNP for_IN cyclin_NN E_NNP (_( panel_NN D_NNP )_) shows_VBZ expression_NN in_IN
          occasional_JJ nuclei_NN ._. The_DT insert_NN shows_VBZ a_DT lack_NN of_IN Ki_NNP 67_CD
          +_NN dividing_VBG cells_NNS ._. Expression_NNP of_IN p_NN 21_CD (_( panel_NN E_NNP )_) is_VBZ similar_JJ
          to_TO that_DT of_IN cyclin_NN E_NNP ._. The_DT pRb_NN (_( panel_NN F_NN )_) shows_VBZ nuclear_JJ
          expression_NN similar_JJ to_TO that_DT of_IN p_NN 27_CD ,_, including_VBG stromal_NN
          cells_NNS ,_, but_CC no_DT cytoplasmic_JJ staining_VBG of_IN luteal_NN cells_NNS ._.
          These_DT observations_NNS indicate_VBP that_IN cytoplasmic_JJ
          expression_NN of_IN p_NN 27_CD correlates_NNS with_IN that_DT of_IN cyclin_NN D_NNP 1_CD ._. One_PRP
          may_MD speculate_VB that_IN the_DT cdk_NN 4_CD is_VBZ involved_VBN ,_, since_IN p_NN 27_CD has_VBZ a_DT
          preferential_JJ affinity_NN to_TO the_DT cyclin_NN D-_NNP cdk_NN 4_CD complex_JJ ._. If_IN
          the_DT cytoplasmic_JJ p_NN 27_CD expression_NN in_IN abnormal_JJ muscle_NN cells_NNS
          is_VBZ accompanied_VBN by_IN staining_VBG for_IN cyclin_NN D_NNP 1_CD ,_, remains_VBZ ,_,
          however_RB ,_, to_TO be_VB established_VBN ._.
        
      
      
        Conclusions_NNP
        This_DT is_VBZ a_DT first_JJ report_NN on_IN the_DT p_NN 27_CD protein_NN expression_NN in_IN
        normal_JJ and_CC abnormal_JJ human_JJ striated_JJ muscle_NN cells_NNS 
        in_IN vivo_NN ._. Normal_NNP muscle_NN fibers_NNS show_VBP
        strong_JJ nuclear_JJ and_CC plasma_NN membrane_NN expression_NN ._. Cytoplasmic_NNP
        p_NN 27_CD staining_VBG accompanies_VBZ perimenopausal_NN transition_NN of_IN type_NN
        II_NNP to_TO type_NN I_PRP fibers_NNS ._. In_IN the_DT absence_NN of_IN other_JJ muscle_NN
        abnormalities_NNS ,_, the_DT diminution_NN of_IN type_NN II_NNP fibers_NNS alone_RB is_VBZ
        not_RB necessarily_RB accompanied_VBN by_IN PFD_NNP ._. Pelvic_NNP floor_NN disorders_NNS
        in_IN perimenopausal_NN patients_NNS are_VBP associated_VBN with_IN the_DT
        hypertrophy_NN of_IN muscle_NN cells_NNS and_CC moderate_JJ cytoplasmic_JJ p_NN 27_CD
        expression_NN ,_, while_IN PFD_NNP during_IN advanced_JJ postmenopause_NN are_VBP
        associated_VBN with_IN shrinking_VBG and_CC fragmentation_NN of_IN muscle_NN cells_NNS
        and_CC cytoplasmic_JJ p_NN 27_CD overexpression_NN ._. The_DT cytoplasmic_JJ and_CC
        plasma_NN membrane_NN p_NN 27_CD expression_NN is_VBZ not_RB unique_JJ to_TO the_DT muscle_NN
        cells_NNS ,_, since_IN it_PRP can_MD also_RB be_VB detected_VBN to_TO occur_VB ,_, at_IN least_JJS
        temporarily_RB ,_, in_IN other_JJ cell_NN types_NNS ._.
      
      
        List_NN of_IN Abbreviations_NNP
        PFD_NNP ,_, pelvic_JJ floor_NN disorders_NNS ;_: p_NN 27_CD ,_, p_NN 27_CD kip_NN 1_CD ;_: PBS_NNP ,_,
        phosphate-buffered_JJ saline_NN ;_: CL_NNP ,_, corpus_NN luteum_NN or_CC corpora_NN
        lutea_NN ;_: cdk_NN ,_, cyclin-dependent_JJ kinase_NN ;_: p_NN 21_CD ,_, p_NN 21_CD
        Cip_NNP 1_CD /_NN WAF_NNP 1_CD ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
    
  
